Last deal

$49M

Amount

Post-IPO Equity

Stage

01.09.2009

Date

3

all rounds

$88.5M

Total amount

date founded

Financing round

General

About Company
Momenta Pharmaceuticals, Inc. is a biotechnology company.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2001

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company has a diversified product pipeline that includes complex generic, follow-on biologic, and novel drugs. Momenta's two most advanced complex generic product candidates target marketed products, Lovenox and Copaxone. In addition to its legacy business, Momenta is focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases using its scientific platform based on a deep understanding of immune biology and disease analytics.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Kleo

Kleo

Kleo Pharmaceuticals develops immunotherapy compounds to target cancer cells.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

New Haven, CT, USA

total rounds

3

total raised

$32M
Adriacell

Adriacell

Adriacell is a biotech company focused on developing solutions for tumors with low survival rates and anti-infective agents.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

34149 Basovizza, Province of Trieste, Italy
Immune Biosolutions

Immune Biosolutions

Immune Biosolutions is a biotech company that specializes in the discovery and engineering of chicken edible and humanized antibodies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care

Location

Sherbrooke, QC, Canada

total rounds

3

total raised

$11.05M
A2A Pharmaceuticals

A2A Pharmaceuticals

A2A Pharmaceuticals Inc.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

New York, NY, USA

total rounds

2
M&A Details
1

Acquired by

Johnson & Johnson

announced date

19.08.2020

price

$6.5B

Financials

Funding Rounds
3
3

Number of Funding Rounds

$88.5M

Money Raised

Their latest funding was raised on 01.09.2009. Their latest round Post-IPO Equity

Polaris Partners

Polaris Partners

Polaris Partners is a venture capital firm that invests in healthcare and technology companies at all stages of growth.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Boston, MA, USA

count Of Investments

557

count Of Exists

135
MVM Life Science Partners

MVM Life Science Partners

MVM Life Science Partners is a venture capital firm that invests in healthcare companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Health Care, Life Science, Pharmaceuticals

Location

London, UK

count Of Investments

67

count Of Exists

16
Cardinal Partners

Cardinal Partners

Cardinal Partners is a venture capital firm based in Princeton, New Jersey, that invests in early-stage companies in the healthcare sector.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Health Care, Financial Services

Location

Princeton, NJ, USA

count Of Investments

52

count Of Exists

13

Mithra Ventures

Mithra Group is a venture capital firm that invests in high-growth life sciences companies in the US and India.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Boston, MA, USA

count Of Investments

3

count Of Exists

1
Atlas Venture

Atlas Venture

Atlas Venture invests in biotech startups with seed and early stage venture investments.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Venture Capital, Financial Services, Biotechnology

Location

Cambridge, MA, USA

total rounds

1

count Of Investments

444

count Of Exists

146
Cardinal Partners

Cardinal Partners

Cardinal Partners is a venture capital firm based in Princeton, New Jersey, that invests in early-stage companies in the healthcare sector.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Health Care, Financial Services

Location

Princeton, NJ, USA

count Of Investments

52

count Of Exists

13
MVM Life Science Partners

MVM Life Science Partners

MVM Life Science Partners is a venture capital firm that invests in healthcare companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Health Care, Life Science, Pharmaceuticals

Location

London, UK

count Of Investments

67

count Of Exists

16
Atlas Venture

Atlas Venture

Atlas Venture invests in biotech startups with seed and early stage venture investments.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Venture Capital, Financial Services, Biotechnology

Location

Cambridge, MA, USA

total rounds

1

count Of Investments

444

count Of Exists

146
Polaris Partners

Polaris Partners

Polaris Partners is a venture capital firm that invests in healthcare and technology companies at all stages of growth.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Boston, MA, USA

count Of Investments

557

count Of Exists

135
Co-Investors
Investors
5
5

Number of lead investors

5

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series B, Series C
Yes
Series B, Series C
Yes
Series B, Series C
Cardinal Partners

Cardinal Partners

Cardinal Partners is a venture capital firm based in Princeton, New Jersey, that invests in early-stage companies in the healthcare sector.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Health Care, Financial Services

Location

Princeton, NJ, USA

count Of Investments

52

count Of Exists

13
MVM Life Science Partners

MVM Life Science Partners

MVM Life Science Partners is a venture capital firm that invests in healthcare companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Health Care, Life Science, Pharmaceuticals

Location

London, UK

count Of Investments

67

count Of Exists

16
Atlas Venture

Atlas Venture

Atlas Venture invests in biotech startups with seed and early stage venture investments.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Venture Capital, Financial Services, Biotechnology

Location

Cambridge, MA, USA

total rounds

1

count Of Investments

444

count Of Exists

146
Peter Barrett

Peter Barrett

Barrett joined Atlas Venture, an early stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics. Prior to that, Mr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development. He currently serves as a director of Vitae Pharmaceuticals, Inc. and Zafgen, Inc., as well as several privately held companies, and during the past five years has served as a director of Akela Pharma, Inc., Alnylam Pharmaceuticals, Inc., Helicos BioSciences Corporation, Momenta Pharmaceuticals, Inc. and SciClone Pharmaceuticals, Inc. Mr. Barrett is currently Vice Chairman of the Advisory Council of the Barrett Institute of Chemical and Biological Analysis at Northeastern University, as well as Adjunct Professor at the Barrett Institute. He also serves as President of the Autism Consortium, a non-profit institution. Mr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his Doctoral degree in analytical chemistry from Northeastern University. Mr. Barrett has approximately 25 years of experience in the life sciences industry, having served in leadership positions both as a senior executive and as an institutional investor. These roles have allowed him to develop expertise in the deployment of strategic growth initiatives within the industry. His service on the board of directors of other companies, both publicly traded and privately held, enables him to assist our board in the performance of its governance obligations.

current job

Atlas Venture
Atlas Venture

count Of Investments

1

count Of Exists

1
Acquisitions
2
Acquiree Name 
Date 
Price 
Acquisition Name 
Virdante Pharmaceuticals acquired by Momenta Pharmaceuticals

Virdante Pharmaceuticals acquired by Momenta Pharmaceuticals

acquirer

Momenta Pharmaceuticals
Momenta Pharmaceuticals

date

05.12.2011

type

Acquisition

price

$51.5M
Virdante Pharmaceuticals

Virdante Pharmaceuticals

Virdante Pharmaceuticals develops and commercializes drugs for autoimmune and inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Biopharma

Location

Cambridge, MA, USA

total rounds

2

total raised

$60.08M

Parivid acquired by Momenta Pharmaceuticals

acquirer

Momenta Pharmaceuticals
Momenta Pharmaceuticals

date

10.05.2007

type

Acquisition

Parivid

Parivid offers data integration and analysis services.

Sector

Industrial Support Services

Subsector

Professional Business Support Services

Location

Cambridge, MA, USA

People

Founders
5
Ram Sasisekharan
Ram Sasisekharan

Ram Sasisekharan

current job

Tychan
Tychan

organization founded

4

Ram Sasisekharan

Ganesh Venkataraman Kaundinya
Ganesh Venkataraman Kaundinya

Ganesh Venkataraman Kaundinya

Dr. Ganesh Venkataraman Kaundinya, Ph.D., is Senior Vice President - Research, Chief Scientific Officer of Momenta Pharmaceuticals Inc. He is a co-founder of our company and has been our Chief Scientific Officer since September 2007 and our Senior Vice President, Research since April 2005. From January 2002 through April 2005, he served as our Vice President, Technology. Dr. Kaundinya received his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

current job

GlycoEra
GlycoEra

organization founded

1

Ganesh Venkataraman Kaundinya

Mallik Sundaram
Mallik Sundaram

Mallik Sundaram

Dr. Mallik Sundaram co-founded Mitra Biotech in 2008. He serves as the President & CEO of Mitra Biotech since May 2008. Prior to Mitra, Mallik was a scientific co-founder of Momenta Pharmaceuticals (Nasdaq: MNTA) which was founded on the sequencing technology for Complex polysaccharides and glycoproteins, co-developed by Mallik at Dr. Sasisekharan laboratory at MIT. Mallik was instrumental in developing M-Enoxaparin, Momenta’s first Billion dollar drug and three other lead drug candidates through various stages of regulatory approval in the U.S. Mallik obtained his Ph.D. in Biotechnology from the University of Utah, Salt Lake City, and MBA from the Wharton Business School, University of Pennsylvania. He has been an adjunct faculty in the Department of Bioengineering (2000-2007) and the Department of Chemical Engineering (2007-present) at the Massachusetts Institute of Technology, Cambridge, MA.

current job

Farcast
Farcast

organization founded

2

Mallik Sundaram

Christoph Westphal
Christoph Westphal

Christoph Westphal

Christoph Westphal is the Co-Founder, Chairman & Board Member at ImmuneID.

current job

ImmuneID
ImmuneID

Christoph Westphal

Employee Profiles
159

Michael Zelasky

Director,biostatistician

Rao Koduri

Associate director, downstream process development

Rebecca Koeper

Qa gmp consultant

James Prescott

Senior director analytical development

Kelly Beaumont

Executive assistant, legal and finance

Aleksandar Cvetkovic

Senior director, head of bioprocess development

Julie Dumas

Principal business analyst

Anita Wo

Biologics process development associate

Activity

Recent News
1